Invitrogen

CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience™

CD261 (DR4) Antibody in Flow Cytometry (Flow)

FIGURE: 1 / 7

CD261 (DR4) Antibody (12-6644-42) in Flow

Staining of human CD261-transfected cells with Anti-Human CD261 (DR4) Biotin followed by Streptavidin PE (Product # 12-4317-87). Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.

Product Image Gallery

Product Details

12-6644-42

Applications

Tested Dilution

Publications

Immunohistochemistry (Frozen) (IHC (F))

View 1 publication 1 publication

Flow Cytometry (Flow)

5 µL (0.5 µg)/test

View 25 publications 25 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

DJR1

Conjugate

PE PE PE

Excitation/Emission Max

565/576 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4°C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

AB_10852861

Product Specific Information

Description: The DJR1 monoclonal antibody reacts with human DR4, also known as TRAIL-R1. DR4 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR4 is expressed by a variety of human tumor cells and at very low level on human leukocytes.

Expression has also been found inside the cell on some cell lines (Zhang et al). This has been confirmed with intracellular staining of Jurkat cell line. Please contact tech@ebioscience.com for more information.

Applications Reported: The DJR1 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This DJR1 antibody has been pre-titrated and tested by flow cytometric analysis of human DR4-transfected cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

How to use the Panel Builder

Watch the video to learn how to use the Invitrogen Flow Cytometry Panel Builder to build your next flow cytometry panel in 5 easy steps.

Product References

Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells.

Biology

Chiawpanit C,Panwong S,Sawasdee N,Yenchitsomanus PT,Panya A

12-6644-42 was used in Flow cytometry/Cell sorting to demonstrate the effects of genistein on reactivation of apoptosis cascade and increase the susceptibility of Cholangiocarcinoma cells to natural killer (NK-92) cells.

Sat Jul 23 00:00:00 UTC 2022

Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors.

International journal of molecular medicine

Sawasdee N,Wattanapanitch M,Thongsin N,Phanthaphol N,Chiawpanit C,Thuwajit C,Yenchitsomanus PT,Panya A

12-6644-42 was used in Flow cytometry/Cell sorting to support the use of combined doxorubicin and NK immunotherapy in BC treatment.

Tue Mar 01 00:00:00 UTC 2022

Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking.

Cell death and differentiation

Fauster A,Rebsamen M,Willmann KL,César-Razquin A,Girardi E,Bigenzahn JW,Schischlik F,Scorzoni S,Bruckner M,Konecka J,Hörmann K,Heinz LX,Boztug K,Superti-Furga G

12-6644 was used in Flow cytometry/Cell sorting to investigate the genetic basis underlying necroptotic cell death.

Sat Jun 01 00:00:00 UTC 2019

Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking.

Cell death and differentiation

Fauster A,Rebsamen M,Willmann KL,César-Razquin A,Girardi E,Bigenzahn JW,Schischlik F,Scorzoni S,Bruckner M,Konecka J,Hörmann K,Heinz LX,Boztug K,Superti-Furga G

12-6644 was used in Flow cytometry/Cell sorting to investigate the genetic basis underlying necroptotic cell death.

Sat Jun 01 00:00:00 UTC 2019

Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.

International journal of oncology

Kim SL,Min IS,Park YR,Lee ST,Kim SW

12-6644-42 was used in Flow Cytometry to suggest that LCN2 is responsible for TRAIL sensitivity and LCN2 may thus prove to be a promising target protein in DR-targeted CRC therapy.

Sat Dec 01 00:00:00 UTC 2018

Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways.

Oncotarget

Ivanov VN,Wu J,Hei TK

12-6644 was used in Flow cytometry/Cell sorting to demonstrate that radiation-induced death in glioblastoma could be enhanced by CBD-mediated signaling.

Tue Sep 26 00:00:00 UTC 2017

Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.

Molecular cancer therapeutics

Milutinovic S,Kashyap AK,Yanagi T,Wimer C,Zhou S,O'Neil R,Kurtzman AL,Faynboym A,Xu L,Hannum CH,Diaz PW,Matsuzawa S,Horowitz M,Horowitz L,Bhatt RR,Reed JC

12-6644 was used in Functional assays to investigate the use of dual agonist antibodies against DR4 and DR5 to induce cancer cell death, showing promise in future therapy.

Fri Jan 01 00:00:00 UTC 2016

Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Stem cells (Dayton, Ohio)

Redjal N,Zhu Y,Shah K

12-6644 was used in Flow cytometry/Cell sorting to screen clinically relevant chemotherapeutic agents for their ability to sensitise resistant glioblastoma multiforme cell lines to TRAIL induced apoptosis.

Thu Jan 01 00:00:00 UTC 2015

Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.

PloS one

Hwang MH,Li XJ,Kim JE,Jeong SY,Lee SW,Lee J,Ahn BC

12-6644 was used in Flow cytometry/Cell sorting to explore the therapeutic effect of natural killer cells on human doxorubicin-sensitive and resistant breast adenocarcinoma.

Mon May 16 00:00:00 UTC 2016

TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.

PloS one

Chandrasekaran S,Marshall JR,Messing JA,Hsu JW,King MR

12-6644 was used in Flow cytometry/Cell sorting to show that culturing breast cancer cell lines as 3D tumor spheroids results in higher resistance to TRAIL-mediated apoptosis.

Thu Dec 24 00:00:00 UTC 2015

Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.

PloS one

Boyko-Fabian M,Niehr F,Distel L,Budach V,Tinhofer I

12-6644 was used in Flow cytometry/Cell sorting to investigate the causal relationship between p53 deficiency and arsenic trioxide sensitivity.

Wed Dec 09 00:00:00 UTC 2015

Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.

Oncogene

Bagci-Onder T,Agarwal A,Flusberg D,Wanningen S,Sorger P,Shah K

12-6644 was used in Flow cytometry/Cell sorting to investigate the molecular dynamics of TRAIL-based combination therapies for cancer treatment.

Thu Jun 06 00:00:00 UTC 2013

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

PloS one

Turner A,Li LC,Pilli T,Qian L,Wiley EL,Setty S,Christov K,Ganesh L,Maker AV,Li P,Kanteti P,Das Gupta TK,Prabhakar BS

12-6644 was used in Flow cytometry/Cell sorting to investigate how strategies to decrease MADD expression in breast cancer may be utilised to increase tumour cell sensitivity to TRAIL and doxorubicin induced apoptosis.

Wed Aug 28 00:00:00 UTC 2013

The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.

The Journal of biological chemistry

Zhang N,Wang X,Huo Q,Li X,Wang H,Schneider P,Hu G,Yang Q

12-6644 was used in Flow cytometry/Cell sorting to point to a protective function of Metadherin (MTDH) against TRAIL-induced death.

Fri Mar 29 00:00:00 UTC 2013

Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.

Blood

Hanada K,Wang QJ,Inozume T,Yang JC

12-6644 was used in Flow cytometry/Cell sorting to elucidate the nature of the ligand for a α/β TCR that lyses renal cell carcinoma cells regardless of MHC type.

Thu May 05 00:00:00 UTC 2011

A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.

Proceedings of the National Academy of Sciences of the United States of America

Dompe N,Rivers CS,Li L,Cordes S,Schwickart M,Punnoose EA,Amler L,Seshagiri S,Tang J,Modrusan Z,Davis DP

12-6644 was used in Flow cytometry/Cell sorting to highlight a 8q22 gene cluster-mediated mechanism by which cancer cells may evade apoptosis.

Tue Oct 25 00:00:00 UTC 2011

Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Neuro-oncology

Nagane M,Shimizu S,Mori E,Kataoka S,Shiokawa Y

12-6644 was used in Flow cytometry/Cell sorting to suggest that anti-TRAIL-receptor2 (DR5) is the predominant TRAIL receptor mediating apoptotic signals in human glioma cells.

Thu Jul 01 00:00:00 UTC 2010

TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.

BMC musculoskeletal disorders

Bisgin A,Terzioglu E,Aydin C,Yoldas B,Yazisiz V,Balci N,Bagci H,Gorczynski RM,Akdis CA,Sanlioglu S

12-6644 was used in Flow cytometry/Cell sorting to study disease severity in patients with rheumatoid arthritis via TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells.

Fri Aug 27 00:00:00 UTC 2010

c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.

Molecular cancer

Fu L,Lin YD,Elrod HA,Yue P,Oh Y,Li B,Tao H,Chen GZ,Shin DM,Khuri FR,Sun SY

12-6644 was used in Flow cytometry/Cell sorting to investigate the mechanisms by which perifosine enhances TRAIL-induced apoptosis.

Mon Dec 20 00:00:00 UTC 2010

CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.

Cancer research

Lin YD,Chen S,Yue P,Zou W,Benbrook DM,Liu S,Le TC,Berlin KD,Khuri FR,Sun SY

12-6644 was used in Flow cytometry/Cell sorting to reveal a novel mechanism underlying flexible heteroarotinoid-induced apoptosis that involves induction of death receptor 5.

Tue Jul 01 00:00:00 UTC 2008

Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer.

Cancer research

Hyer ML,Shi R,Krajewska M,Meyer C,Lebedeva IV,Fisher PB,Reed JC

12-6644 was used in Flow cytometry/Cell sorting to suggest CDDO and related synthetic triterpenoids should be further evaluated as potential novel therapeutics for hormone refractory prostate cancers.

Tue Apr 15 00:00:00 UTC 2008

The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.

The Journal of biological chemistry

Sun SY,Liu X,Zou W,Yue P,Marcus AI,Khuri FR

12-6644 was used in Flow cytometry/Cell sorting to investigate the underlying mechanism by which farnesyltransferase inhibitors cause growth arrest or apoptosis in cancer cells, showing that it induces expression of death receptor 5.

Fri Jun 29 00:00:00 UTC 2007

Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.

Hepatology (Baltimore, Md.)

Ishiyama K,Ohdan H,Ohira M,Mitsuta H,Arihiro K,Asahara T

Wed Feb 01 00:00:00 UTC 2006

Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

The Journal of neuroscience : the official journal of the Society for Neuroscience

Song JH,Bellail A,Tse MC,Yong VW,Hao C

12-6644 was used in Flow cytometry/Cell sorting to identify the molecular mechanisms that protect normal human astrocytes from apoptosis induced by Fas ligand and TRAIL.

Wed Mar 22 00:00:00 UTC 2006

Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.

Cancer gene therapy

VanOosten RL,Earel JK,Griffith TS

12-6644 was used in Flow cytometry/Cell sorting to investigate the tumouricidal potential of a recombinant adenovirus encoding human TNFSF10.

Thu Jun 01 00:00:00 UTC 2006

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Cancer research

Hyer ML,Croxton R,Krajewska M,Krajewski S,Kress CL,Lu M,Suh N,Sporn MB,Cryns VL,Zapata JM,Reed JC

12-6644 was used in Flow cytometry/Cell sorting to investigate methods to sensitise cancer cells to TRAIL.

Wed Jun 01 00:00:00 UTC 2005

c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.

Cancer research

Zou W,Liu X,Yue P,Zhou Z,Sporn MB,Lotan R,Khuri FR,Sun SY

12-6644 was used in Flow cytometry/Cell sorting to show that activation of JNK pathway results in CDDO-Me-induced DR up-regulation, caspase-8 activation, and apoptosis.

Fri Oct 15 00:00:00 UTC 2004

Bioinformatics

Protein Aliases: CD261; cytotoxic TRAIL receptor; Death receptor 4; MGC9365; sCD261; soluble CD261; soluble TRAIL; sTRAIL; TNF-related apoptosis-inducing ligand receptor 1; TRAIL R1; TRAIL receptor 1; TRAIL-R1; Tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily member 10a variant 2; tumor necrosis factor receptor superfamily, member 10a

View more View less

Gene Aliases: APO2; CD261; DR4; TNFRSF10A; TRAILR-1; TRAILR1

View more View less

UniProt ID: (Human) O00220

View more View less

Entrez Gene ID: (Human) 8797

View more View less

Function(s)

protease binding receptor activity tumor necrosis factor-activated receptor activity death receptor activity protein binding transcription factor binding TRAIL binding

Process(es)

apoptotic process activation of cysteine-type endopeptidase activity involved in apoptotic process inflammatory response immune response signal transduction cell surface receptor signaling pathway activation of NF-kappaB-inducing kinase activity multicellular organism development extrinsic apoptotic signaling pathway via death domain receptors response to lipopolysaccharide tumor necrosis factor-mediated signaling pathway TRAIL-activated apoptotic signaling pathway regulation of cell proliferation regulation of apoptotic process cellular response to mechanical stimulus extrinsic apoptotic signaling pathway activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway regulation of extrinsic apoptotic signaling pathway via death domain receptors negative regulation of extrinsic apoptotic signaling pathway via death domain receptors

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience™

CD261 (DR4) Antibody (12-6644-42) in Flow

Product Details

12-6644-42

Immunohistochemistry (Frozen) (IHC (F))

Flow Cytometry (Flow)

Species Reactivity

Published species

Host/Isotype

Recommended Isotype Control

Class

Type

Clone

Conjugate

Excitation/Emission Max

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

How to use the Panel Builder

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!